Results 71 to 80 of about 4,266 (228)

Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis

Journal of Orthopaedic Translation
Background: Romosozumab is a novel monoclonal antibody that binds to sclerostin, and has dual effects of increasing bone formation and decreasing bone resorption, giving it a unique mechanism of action.
Ronald Man Yeung Wong, Pui Yan Wong, Chaoran Liu, Hei Yuet Wong, Man Ki Fong, Ning Zhang, Wing Hoi Cheung, Sheung Wai Law   +7 more
doaj   +1 more source

Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist

Bone Reports, 2022
Preventing osteoporotic fractures is an issue requiring urgent attention to reduce mortality. However, unlike chronic kidney disease-mineral and bone disorder (CKD-MBD), osteoporosis is inadequately addressed in patients undergoing chronic dialysis.
Masatomo Ogata, Shu Ushimaru, Rie Fujishima, Hirofumi Sumi, Kazuhiro Shiizaki, Naoto Tominaga   +5 more
doaj   +1 more source

Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in postmenopausal women with osteoporosis. [PDF]

JBMR Plus
DXA-based 3D-modeling (3D-DXA) of the hip was used to assess estimated changes in bone integral, cortical, and trabecular parameters and analyze 3D anatomical distribution of changes in bone parameters over time in women who transitioned to romosozumab ...
Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y, Winzenrieth R, Ferrari S, Omura F.   +8 more
europepmc   +2 more sources

2D copper nanozyme patches facilitate bone regeneration via interfacial modulation of osteoclast‐osteoblast dynamics

BMEMat, EarlyView.
This study develops a nano‐enzyme patch (ezPatch) targeting bone interfaces. Utilizing ligand‐to‐metal charge transfer (LMCT) catalysis and bone‐targeting ligands on copper nanosheets, ezPatch simultaneously scavenges reactive oxygen species (ROS) and generates oxygen in situ at bone‐losing sites.
Yi Chen, Haoyue Hu, Danyang Wang, Ying Wang, Zhibang Li, Xiaoyi Liu, Yandi Zhang, Junkun Feng, Weiwei Zhao, Kai Li, Qi‐Zhi Zhong, Shaohua Ge, Jianhua Li   +12 more
wiley   +1 more source

Discontinuing Long‐Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?

Clinical Pharmacology &Therapeutics, EarlyView.
Discontinuation of denosumab (Dmab) may be necessary due to adverse events or an unfavorable long‐term risk–benefit profile. However, accumulating evidence demonstrates pronounced rebound phenomena after withdrawal, most notably a marked increase in multiple vertebral fractures, and, in some reports, elevated mortality.
Ko‐Hsiu Lu, Renn‐Chia Lin, Ing‐Lin Chang, Shau‐Huai Fu, Meng‐Ying Tsai, Shun‐Fa Yang   +5 more
wiley   +1 more source

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis

Osteoporosis International
In severe osteoporosis, the optimal approach for sequential treatment between denosumab and romosozumab is unclear. We utilised a novel overlapping strategy in three patients with very-high fracture risk despite long-term denosumab which led to greater ...
Shejil Kumar, M. Gild, Michelle M. McDonald, Albert S. Kim, Roderick J. Clifton-Bligh, C. Girgis   +5 more
semanticscholar   +1 more source

Advanced Molecular Imaging Probes for Skeletal Diseases: Current Progress and Future Perspectives

iRADIOLOGY, EarlyView.
This review summarizes the potential molecular imaging techniques and probes for common orthopedic diseases, such as trauma, infection, metabolism, tumor, joint, spine and other fields, aiming to provide a basis for the development of a new generation of molecular imaging probes.
Shuo Guo, Yuling Cui, Zhiye Fan, Chenxin Jiang, Bowen Fu, Guangbin Cui, Yanli He   +6 more
wiley   +1 more source

Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis

Journal of Bone and Mineral Metabolism
In the management of osteoporosis, anti-resorptive agents serve as a primary therapeutic approach. However, in cases where individuals exhibit an increased susceptibility to fractures, such as those characterized by severe low bone mass or a history of ...
Kosuke Ebina, Y. Etani, T. Noguchi, Ken Nakata, S. Okada   +4 more
semanticscholar   +1 more source

Romosozumab in Postmenopausal Women with Low Bone Mineral Density.

, 2014
peer reviewedBackground Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation.
Brown, Jacques P., Katz, Leonid, McClung, Michael R., Bolognese, Michael A., Diez-Perez, Adolfo, Langdahl, Bente L., Grauer, Andreas, Bone, Henry G., Yang, Yu-Ching, Wasserman, Scott M., Zanchetta, Jose R., Maddox, Judy, Reginster, Jean-Yves, Libanati, Cesar, Boonen, Steven   +14 more
core   +1 more source

Mind the Gap: Predictors of Osteoporosis Treatment Following Fragility Fracture in Parkinsonism

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Fracture risk is increased in Parkinson's yet this risk is often not addressed. Objectives Our objective was to study the extent to which osteoporosis was treated, and predictors of treatment in a large representative cohort with parkinsonism.
Katie C. Naylor, Emily J. Henderson, Emma Tenison   +2 more
wiley   +1 more source